Should You Buy Sarepta Stock At $71?
We believe that the stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, is undervalued at current levels of $71. SRPT stock is down 20% off the March 2020 bottom compared...
Source: forbes.com